Last Update Time:
12-Mar-2025 16:00:00
ISIN:
INE376G01013
Sector:
Healthcare
Symbol:
BIOCON
Biocon Limited
₹325.00
₹-3.90
(-1.19%)
▼
Prev. Close
₹328.90
Open
₹328.15
Close
₹325.10
Range
₹308.75 - ₹341.25
High
₹330.90
Low
₹323.40
Ind. Close
₹0.00
VWAP
₹325.30
The current stock price of Biocon Limited is ₹325.00, with a target price range between ₹308.75 and ₹341.25. The stock has experienced a price change of ₹-3.90 (-1.19%), reflecting recent market volatility.
Today's opening price was ₹328.15, while the previous close stood at ₹328.90.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Biocon Limited Price Chart
Biocon Limited Pre Open Market Overview: 12-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 328.15
- Previous Close Price: 328.9
- Change: -0.75%
- Total Traded Volume: 3,108
- Total Buy Quantity: 16,598
- Total Sell Quantity: 37,452
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 326.90 | 10.00 | 0.00 |
| 327.00 | 30.00 | 0.00 |
| 327.15 | 2,000.00 | 0.00 |
| 328.00 | 198.00 | 0.00 |
| 328.15 | 768.00 | 0.00 |
| 328.90 | 0.00 | 315.00 |
| 329.00 | 0.00 | 179.00 |
| 329.85 | 0.00 | 100.00 |
| 330.00 | 0.00 | 115.00 |
| 330.30 | 0.00 | 100.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 16598
Total Sell Quantity: 37452
Shareholding Patterns of Biocon Limited
Key Trade Statistics of Biocon Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 17.83 |
| Traded Value (₹ Cr.) | 58.00 |
| Total Market Cap (₹ Cr.) | 39,019.50 |
| Free Float Market Cap (₹ Cr.) | 14,595.09 |
| Impact cost | 0.04 |
| Quantity Traded | 1,782,978.00 |
| Deliverable Quantity | 772,496.00 |
| % of Quantity to Traded | 43.33 |
| Security VaR | 14.59 |
| Index VaR | N/A |
| VaR Margin | 14.59 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 18.09 |
| Face Value | 5 |
Key Price Statistics of Biocon Limited
The 52-week high for Biocon Limited was ₹404.70, recorded on 21-Jan-2025. On the other hand, the 52-week low stands at ₹244.55, with the lowest value recorded on 20-Mar-2024.
The upper band for trading is ₹361.75, and the lower band is ₹296.05. The price band is No Band%.
The stock's daily volatility stands at 2.27, while the annualized volatility is 43.37. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (21-Jan-2025) | 404.70 |
| 52 Week Low (20-Mar-2024) | 244.55 |
| Upper Band | 361.75 |
| Lower Band | 296.05 |
| Price Band (%) | No Band |
| Daily Volatility | 2.27 |
| Annualised Volatility | 43.37 |
| Tick Size | 0.05 |
Key Securities Statistics of Biocon Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 07-Apr-2004 |
| Adjusted P/E | 34.32 |
| Symbol P/E | 33.03 |
| Index | NIFTY PHARMA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Biocon Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Biocon Limited
| Subject | Date |
|---|---|
| Press Release | 07-Mar-2025 |
| Press Release | 06-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 06-Mar-2025 |
| General Updates | 04-Mar-2025 |
| Press Release | 04-Mar-2025 |
| Press Release | 28-Feb-2025 |
| Copy of Newspaper Publication | 28-Feb-2025 |
| Press Release | 28-Feb-2025 |
Corporate Actions of Biocon Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 5 | Dividend - Re 0.50 Per Share | 05-Jul-2024 |
| 5 | Dividend - Rs 1.50 Per Share | 07-Jul-2023 |
| 5 | Dividend - Rs 0.50 Per Share | 30-Jun-2022 |
| 5 | Dividend - Rs 0.50 Per Share | 18-Jul-2019 |
| 5 | Bonus 1:1 | 12-Jun-2019 |
| 5 | Dividend- Re 1 Per Share | 19-Jul-2018 |
| 5 | Annual General Meeting/Dividend - Re 1/- Per Share | 20-Jul-2017 |
| 5 | Bonus 2:1 | 15-Jun-2017 |
| 5 | Annual General Meeting | 22-Jun-2016 |
| 5 | Interim Dividend - Rs 5/- Per Share (Purpose Revised) | 17-Mar-2016 |
| 5 | Annual General Meeting | 16-Jul-2015 |
| 5 | Interim Dividend Rs 5/- Per Share | 09-Apr-2015 |
| 5 | Annual General Meeting / Final Dividend - Rs 5/- Per Share | 10-Jul-2014 |
| 5 | Annual General Meeting/Final Dividend Rs 5/- Per Share + Special Dividend Rs 2.5/- Per Share | 11-Jul-2013 |
| 5 | Annual General Meeting / Dividend Rs 5 Per Share | 05-Jul-2012 |
| 5 | Annual General Meeting/Dividend Rs 3 Per Share | 07-Jul-2011 |
| 5 | Interim Dividend-Rs.1.50 Per Share (Purpose Revised) | 05-May-2011 |
| 5 | Annual General Meeting And Dividend Rs.3.50 Per Share | 08-Jul-2010 |
| 5 | Agm/Div-Rs.3/- Per Share Bc Start Date Revised | 08-Jul-2009 |
| 5 | Bonus 1:1 | 11-Sep-2008 |
Board Meetings of Biocon Limited
Financial Results of Biocon Limited
Company Directory of Biocon Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.biocon.com | Registered Office | 20th KM Hosur Road Electronic City P.O | BANGALORE |
| www.biocon.com | Transfer Agent | KFin Technologies Limited Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda | HYDERABAD |
Insider Trading of Biocon Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | NEHAL VORA | 15864808 | Pledge |
| 7(2) | SIVANANDAM K | 1880365 | Pledge |
| 7(2) | Akhilesh Nand | 2866050 | Sell |
| 7(2) | KIRAN KUMAR GANDHIRAJAN | 5286351 | Sell |
| 7(2) | SHASHI KANT TIWARI | 1709207 | Buy |
| 7(2) | MANEESH H GHILDYAL | 541900 | Sell |
| 7(2) | MANEESH H GHILDYAL | 1415000 | Sell |
| 7(2) | MANEESH H GHILDYAL | 275800 | Sell |
| 7(2) | SANTOSH GOVINDRAO KATTI | 5628275 | Buy |
| 7(2) | MANEESH H GHILDYAL | 278550 | Sell |
| 7(2) | MANEESH H GHILDYAL | 558400 | Sell |
| 7(2) | MANEESH H GHILDYAL | 277500 | Sell |
| 7(2) | MANEESH H GHILDYAL | 277350 | Sell |
| 7(2) | MANEESH H GHILDYAL | 1362500 | Sell |
| 7(2) | MANEESH H GHILDYAL | 540900 | Sell |
| 7(2) | MANEESH H GHILDYAL | 807540 | Sell |
| 7(2) | MANEESH H GHILDYAL | 271050 | Sell |
| 7(2) | MANEESH H GHILDYAL | 271050 | Sell |
| 7(2) | MANEESH H GHILDYAL | 807540 | Sell |
| 7(2) | SARAVANAN KRISHNAN | 1483622 | Sell |
Annual Reports of Biocon Limited
Investor Complaints of Biocon Limited
Event Calendar of Biocon Limited
| Purpose | Details |
|---|---|
| Results/Dividend | Inter alia, to approve and take on record the audited financial results of the company for the year ended on March 31, 2011 and to consider payment of interim dividend and recommendation of final dividend for the Financial year 2010-2011. |
| Board meeting Rescheduled | The Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on October 20, 2011 inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on September 30, 2011. The Company has now informed the Exchange that the aforesaid Board Meeting has been preponed and will now be held on October 19, 2011. |
| Results/Dividend | Inter alia, to approve and take on record the audited financial results of the Company for the year ended on March 31, 2012 and to consider recommendation of payment of dividend, if any, for the year 2011-2012. |
| Results/Others | Inter alia to : (a) Approve and take on record the unaudited financial results of the Company for the quarter ended on June 30, 2012; (b) Consider merger of Biocon Biopharmaceuticals Limited, a wholly owned subsidiary with the Company. |
| Results/Dividend | inter alia, to: (a) Approve and take on record the audited Financial results for the year ended on March 31, 2013.and (b) Consider recommendation of payment of dividend, if any, for the year 2012-2013. |
| Results | Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended June 30, 2013. |
| Results | Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2013. |
| Results | Inter alia to approve and take on record the unaudited financial results of the Company for the quarter ended December 31, 2013. |
| Results/Dividend | Inter alia, to: (a) Approve and take on record the audited financial results for the year ended on March 31, 2014. (b) Consider recommendation for payment of dividend, if any, for the year 2013-2014. |
| Results | inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended June 30, 2014. |
| Results | Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2014. |
| Results | Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended December 31, 2014. |
| Results | inter alia, to approve and take on record the audited annual financial results of the Company for the financial year ended on March 31, 2015. |
| Results | inter alia, to approve and take on record the un-audited financial results for the quarter ended on June 30, 2015. |
| Results | Inter alia, to approve and take on record the un-audited financial results for the quarter ended on September 30, 2015The Company will organize a conference call for analysts and investors on October 21, 2015. The details of the call will be available on the Company's website closer to the scheduled event. |
| Results | BIOCON : 21-Jan-2016: inter alia, to approve the un-audited financial results for the quarter and period ended on December 31, 2015. |
| Results | inter alia, to approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2016. |
| Results | inter alia, to approve the un-audited financial results for the quarter ended on June 30, 2016 . |
| Results | inter alia, to approve the un-audited financial results for the quarter and period ended on September 30, 2016. |
| Results/Others | Inter alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended December 31, 2016 amongst other routine matters. |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on April 27, 2017 inter alia, to consider, approve and take on record, the audited financial results (both standalone and consolidated) of the Company for the year ended March 31, 2017 amongst other routine matters. The Company has now informed the Exchange that the board also considered and recommendation of final dividend , if any , for the financial year 2016-17.(purpose revised). |
| Results/Others | inter alia, to consider, approve and take on record, the audited financial results (both standalone and consolidated) of the Company for the year ended March 31, 2017 amongst other routine matters. |
| Results/Dividend/Bonus | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on April 27, 2017 inter alia, to consider, approve and take on record, the audited financial results (both standalone and consolidated) of the Company for the year ended March 31, 2017 amongst other routine matters recommendation of final dividend , if any , for the financial year 2016-17. The Company has now informed the Exchange that the board to consider and recommend to issue bonus share.(purpose revised). |
| Results/Others | inter alia, to consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended June 30, 2017 amongst other routine matters. |
| Results | Inter alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter and half year ended September 30, 2017 amongst other routine matters. |
| Results/Others | Inter alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended December 31, 2017 amongst other routine matters. |
| Financial Results/Dividend | The Company had informed the Exchange regarding the Board Meeting Scheduled to be held on April 26, 2018 To consider and approve the financial results for the period ended March 31, 2018 . The Company has now informed the Exchange that consideration and recommendation of f inal dividend, if any, for the financial year 2017-18 forms part of the agenda of the meeting of Board of Directors of the company, scheduled on April26, 2018.(Purposed Revised) |
| Financial Results | Inter alia to consider, approve and take on record, the audited financial results (both standalone and consolidated) of the Company for the quarter/ year ended 31st March, 2018 amongst other routine matters.. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Dividend/Bonus | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on April 25, 2019 To consider and approve the financial results for the period ended March 31, 2019. the Company has now inform the exchange that will also consider and recommend a proposal for dividend and issue of Bonus shares at the scheduled board meeting on April 25, 2019. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2019 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2020 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2020 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2020 and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2021, dividend and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2021 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2021 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2021 and other business matters |
| Financial results | Biocon Limited has informed the Exchange about Board Meeting to be held on 28-Apr-2022 to consider financial statements for the period ended March 2022 |
| Financial results | Biocon Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2022 to consider financial statements for the period ended September 2022. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Fund Raising | Intimation pursuant to Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
| Fund Raising | To consider Fund Raising |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2024 and other business matters |
Share Transfers of Biocon Limited
Voting Results of Biocon Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOCON BIOLOGICS LIMITED AND BIOCON BIOLOGICS GLOBAL PLC, BEING DIRECT AND INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE SALE, DISPOSAL AND LEASING OF ASSETS EXCEEDING 20% OF THE ASSETS OF MATERIAL SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOCON SDN BHD AND BIOSIMILARS NEWCO LIMITED, BEING INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOSIMILAR COLLABORATIONS IRELAND LIMITED AND BIOSIMILARS NEWCO LIMITED, BEING INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOCON BIOLOGICS UK LIMITED AND BIOSIMILARS NEWCO LIMITED, BEING INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOCON BIOLOGICS LIMITED AND BIOSIMILARS NEWCO LIMITED, BEING DIRECT AND INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOCON SDN BHD AND BIOCON BIOLOGICS GLOBAL PLC, BEING INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOSIMILAR COLLABORATIONS IRELAND LIMITED AND BIOCON BIOLOGICS GLOBAL PLC, BEING INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOSIMILARS NEWCO LIMITED AND BIOCON BIOLOGICS GLOBAL PLC, BEING INDIRECT SUBSIDIARIES OF THE COMPANY |
| 22-SEP-2024 | Postal Ballot | TO APPROVE MATERIAL RELATED PARTY TRANSACTION(S) BETWEEN BIOCON BIOLOGICS UK LIMITED AND BIOCON BIOLOGICS GLOBAL PLC, BEING INDIRECT SUBSIDIARIES OF THE COMPANY |
| 09-AUG-2024 | AGM | To receive, consider and adopt the Audited Financial Statements (including audited consolidated financial statements) of the Company for the Financial Year ended March 31, 2024 and the reports of the Board of Directors and Auditors thereon |
| 09-AUG-2024 | AGM | To approve material related party transactions between Biocon Biologics Limited and Biocon Biologics UK Limited, being direct and indirect subsidiaries of the Company |
| 09-AUG-2024 | AGM | To approve grant of Restricted Stock Units to the employees of present and future subsidiary company(ies) under Biocon Restricted Stock Unit Long Term Incentive Plan FY 2025-29 |
| 09-AUG-2024 | AGM | Authorization for secondary acquisition of equity shares of the Company by Biocon India Limited Employees Welfare Trust for implementation of ￢ﾀﾘBiocon Restricted Stock Unit Long Term Incentive Plan FY 2025-29 |
| 09-AUG-2024 | AGM | To approve Biocon Restricted Stock Unit Long Term Incentive Plan FY 2025-29 and grant of Restricted Stock Units to eligible employees of the Company |
| 09-AUG-2024 | AGM | To re-appoint Mr. Siddharth Mittal (DIN: 03230757) as the Managing Director of the Company |
| 09-AUG-2024 | AGM | To re-appoint Ms. Kiran Mazumdar-Shaw (DIN: 00347229) as an Executive Director (designated as an ￢ﾀﾜExecutive Chairperson ) of the Company |
| 09-AUG-2024 | AGM | To appoint Mr. Atul Dhawan (DIN: 07373372) as an Independent Director of the Company |
| 09-AUG-2024 | AGM | To declare a final dividend of 10% i.e. Re. 0.50/- per equity share for the Financial Year ended March 31, 2024 |
| 09-AUG-2024 | AGM | To appoint Mr. Eric Vivek Mazumdar (DIN: 09381549) as Director, liable to retire by rotation, and being eligible, offers himself for re-appointment |
FAQs on Biocon Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.